This document provides an overview of PerkinElmer, a company focused on diagnostics, life sciences, food, and applied markets. It discusses their mission of innovating for a healthier world, with over 80 years of innovations including a COVID-19 PCR kit launched in 2020. The company's diagnostics segment focuses on reproductive health, immunoassays, and applied genomics. PerkinElmer has global capabilities across molecular diagnostics, imaging, automation, and more. It is pursuing growth in areas like single-cell analysis, therapeutics, digital solutions, and decentralized testing. The company's strategy focuses on detection, decentralization, and digitization to drive profitable growth.

1. 1

2. Diagnostics
Passionate about saving and
transforming patients’ lives
Life Sciences
Focused on accelerating pre-clinical
discoveries and enabling customers to
deliver safe and effective therapies
Food
Dedicated to ensuring the highest quality
product and keeping the consumer safe
Applied
Energized by empowering a cleaner
and safer environment
2
WHO WE ARE
INNOVATING
for a
healthier
WORLD
OUR MISSION

3. 3
80+ YEARS OF
INNOVATING FOR A
BETTER TOMORROW

4. WORLD-CLASS INNOVATIONS LAUNCHED IN 2020
4
COVID-19 RT-PCR Kit
LOWEST
LIMIT OF DETECTION
Awarded “2021 World Changing Ideas”

5. 5
WHO WE ARE: NEW PKI
Diagnostics
(Dx)
Discovery
& Analytical
Solutions
(DAS)
$3.8B
2020 Revenue
+15%
increase to LS/Dx mix
40% 35% 25%
AMERICAS EUROPE APAC
+10%
global revenue
75%
25% INSTRUMENTS
CONSUMABLES
SERVICES
SOFTWARE
+15%
recurring revenue
vs 2015
Key:
Select Portfolio Additions
~$3.4B
deployed capital*
* Includes Nexcelom Bioscience, Sirion Biotech, and IDS acquisitions

6. 6
85%
15%
Consumables,
Services,
Software
Instruments
40%
Americas
40%
Europe
20%
Asia
$2.1B
Applied
Genomics
(AG)
ImmunoDx
(IDx)
2020 revenue
Reproductive
Health
(RH) Total
Addressable
Market
(TAM)
$35B+
KEY POSITIONS
Reproductive
Health
Provider of Newborn, NIPT,
biochemical screening, and
pre-eclampsia solutions
#1
ImmunoDx
Extensive menu of across
autoimmune, allergy, and
latent tuberculosis
#2
Applied
Genomics
Leader in Liquid Handling and
RNA/DNA Extraction
#3
DIAGNOSTICS (DX) AT A GLANCE

7. URKU SITE
One of the largest
manufacturing
and R&D facilities in
PerkinElmer

8. Applied
Genomics
INSTRUMENTS
17% 82%
SOFTWARE
1%
REAGENTS
real-time PCR
DNA extraction
Cytogenetics
Infectious diseases
2020
$642M
Revenue
Reproductive
Health
44%
Newborn Health
Maternal Fetal Health
Clinical Diagnostics
56%
CENTRE OF EXCELLENCE FOR DIAGNOSTICS DEVICES

9. OPPORTUNITY TO MAKE A DIFFERENCE
68
BABIES SAVED
EVERY DAY
MILLION
CUMULATIVELY
SCREENED
702
Newborn screening saves lives
OVER 10 MILLION WOMEN
around the world develop
pre-eclampsia annually,
500 000 NEONATAL DEATHs
– with screening and proper
management 62% less adverse
Maternal health

10. COMPLETE
SOLUTIONS
EXCEPTIONAL
ADVANTAGES
PerkinElmer is a leading producer of tests for
prenatal and newborn screening, as well as
sample collection devices, sample preparation and
measuring instruments and informatics to support
the entire screening process from sampling to
follow-up of the screened baby.

11. WHO WE ARE: GLOBAL CAPABILITIES
Molecular Diagnostics
Gene Editing and
Cell Engineering
Immunofluorescence
Drug Discovery Assays
Dried Blood Spot
Platform
Autoimmune Assays
Data Analytics and
Enterprise Software
Mass Spectrometry Detection and Imaging
11
NGS Assays &
Magnetic Beads
Pathogen Detection
Spectroscopy
Workflow Automation

12. FUTURE GROWTH ACCELERATORS
12
New Capabilities add $10B of
Total Addressable Market by 2025
Growing at >20% over the
next 5 years
SINGLE CELL
ANALYSIS
CELL, GENE &
BIOLOGICAL
THERAPIES
DIGITAL LAB OF
THE FUTURE
DECENTRALIZED
TESTING

13. 13
DIAGNOSTICS: MAKING THE COMPLEX VERY SIMPLE
Current Primary
Differentiator
Recent and Accelerating Novel Innovations
ETECTION
Driving best-in-class
breadth and scale and
augmenting through a
complete, modular
workflow
ECENTRALIZATION
Advancing novel
capabilities through a
multi-modal and
ubiquitous approach
IGITIZATION
Increasing simplicity
and convenience
through digital solutions
SUSTAINED PROFITABLE,
HSD+ GROWTH
Underpinned by differentiated
3 “D” STRATEGY

14. 14
NEW PERKINELMER
PORTFOLIO TRANSFORMATION
Expanding into faster growing markets with
greater capabilities
1
OPERATIONAL EXCELLENCE
Better and consistent performance
4
TALENT AND CULTURE
Purpose-driven careers and the best
place to work
5
COMMERCIAL EXECUTION
Larger market share with greater efficiency
3
TECHNOLOGY AND INNOVATION
Faster and more transformative solutions
across PKI
2
US BEFORE ME
WE ARE A TEAM
DO THE RIGHT THING
ALWAYS
PASSION FOR
PEOPLE
TAKE OWNERSHIP AND
GET IT DONE
BETTER CUSTOMER
SOLUTIONS TODAY